Soon afterward, researchers also showed that Par3 expression was significantly upregulated in clinical metastatic prostate cancer (73), hepatocellular carcinoma (94), ovarian cancer (75), colorectal cancer (95), and clear cell renal cell carcinoma (96), which was associated with a poor prognosis (94). The gene discussed is PARD3; the disease is ovarian cancer.